Samarium-153-Lexidronam Complex For Treatment Of Occult Bony Metastases In High-Risk, Clinically Non-Metastatic Prostate Cancer: The First Report Of A Completed Phase I Trial
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS(2008)
Abstract
We completed a Phase I trial to determine the maximum tolerated dose (MTD) of 153Sm Lexidronam administered with neoadjuvant hormonal therapy (NHT) and external beam radiation therapy (RT) in high-risk clinically non-metastatic prostate cancer. The purpose of this radiotherapeutic approach was to safely and effectively treat subclinical bony metastases with a radiopharmaceutical agent in conjunction with NHT and RT. High-risk M0 prostate cancer patients (PSA >20 ng/mL, Gleason score >7, or >T3) were eligible for this prospective trial of dose-escalated radioactive 153Sm Lexidronam (0.25 mCi/kg to 2.0 mCi/kg). After 1 month of total androgen suppression (TAS), we administered 153Sm Lexidronam followed by 4 more months of TAS, 46.8 Gy to the pelvic region and 23.4 Gy to the prostate target (TD = 70.2 Gy). We serially assessed hematologic and serum chemistry parameters. The primary endpoint was Grade III toxicity or higher according to the NCI Common Toxicity Criteria (CTC). Twenty-nine patients enrolled (median PSA = 8.2 ng/mL, 27/29 (93%) T stage ≥T2b, 24/29 (83%) had Gleason >7) and received 153Sm Lexidronam 0.25 mCi/kg (4 patients), 0.5 mCi/kg (4 patients), 0.75 mCi/kg (6 patients), 1.0 mCi/kg (6 patients), 1.5 mCi/kg (5 patients), 2.0 mCi/kg (4 patients). Twenty-eight patients underwent all planned therapy without any delays (1 patient required surgery before the start of RT). With a median follow-up time of 23 months, there were 2 patients (7%) experiencing Grade III hematologic toxicity. There were no other Grade III or IV side effects. There was a significant dose-response relationship in the mean nadir platelet count at 4 weeks after 153Sm Lexidronam administration (p = 0.023). In the 22 patients with testosterone levels available, there was also a significant difference in hemoglobin level between 5 medically castrated patients (testosterone level <50) and 17 non-castrated patients (p = 0.019), median hemoglobin of 11.4 g/dL in medically castrated patients vs. 13.9 g/dL otherwise. These findings demonstrate that the administration of 153Sm Lexidronam at a MTD of 2 mCi/kg with TAS and RT was safe and feasible in patients with high-risk M0 prostate cancer. A Phase II study to test the efficacy of this treatment paradigm will be conducted by the Radiation Therapy Oncology Group.
MoreTranslated text
Key words
Metastatic Prostate Cancer
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined